Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
Feb 7 (Reuters) - Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the telehealth provider for its $49 weight-loss pill.
(Reporting by Anusha Shah in Bengaluru; Editing by Andrea Ricci)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Remittix Set To Eclipse BlockDag After Experts Predict 500% Gains For Holders As Early As Monday
American Air CEO to Hold Talks with Pilots Union Following Criticism
Forget A Bitcoin Yearly Top, BTC Price Might Have Hit A 16-Year Cyclical Peak
Top DeFi Platforms for Staking and Investment: CRO, ATOM, SEI, INJ, TIA, and Others Lead by Total Staked Value
Trending news
MoreCrypto prices
More
